Table 5.
The diagnostic efficiency of models in differentiating early stage NSCLC from BPN/HC
| AUC (95% CI) | Cut-off value | SN (%) | SP (%) | PPV (%) | NPV (%) | Positive LR | Negative LR | |
|---|---|---|---|---|---|---|---|---|
| NSCLC vs. control | ||||||||
| VEGF | 0.747(0.641-0.781) | 67.3 | 64.9 | 91.6 | 88.5 | 72.3 | 7.72 | 0.383 |
| Cyfra 21-1 | 0.633(0.561-0.704) | 3.34 | 54.4 | 71.4 | 65.6 | 61.0 | 1.90 | 0.639 |
| CA125 | 0.667(0.597-0.736) | 13.7 | 52.6 | 77.3 | 69.9 | 62.0 | 2.32 | 0.613 |
| CEA | 0.711(0.641-0.781) | 4.48 | 54.4 | 93.3 | 89.0 | 67.2 | 8.09 | 0.489 |
| VEGF+Cyfra 21-1+CA125+CEA | 0.872(0.822-0.923) | 0.448 | 79.8 | 87.4 | 86.4 | 81.2 | 6.33 | 0.231 |
| NSCLC vs. BPN | ||||||||
| VEGF | 0.765(0.697-0.833) | 78.7 | 63.2 | 95.6 | 93.5 | 72.2 | 14.3 | 0.385 |
| Cyfra 21-1 | 0.684(0.617-0.768) | 3.22 | 59.6 | 75.0 | 70.5 | 65.0 | 2.39 | 0.538 |
| CA125 | 0.620(0.551-0.690) | 10.2 | 73.7 | 54.4 | 61.8 | 67.4 | 1.62 | 0.484 |
| CEA | 0.699(0.630-0.768) | 5.50 | 46.5 | 94.9 | 90.0 | 63.9 | 9.03 | 0.564 |
| VEGF+Cyfra 21-1+CA125+CEA | 0.869(0.818-0.921) | 0.457 | 78.1 | 91.9 | 90.6 | 80.7 | 9.65 | 0.239 |
Abbreviations: LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.